This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MTSR Metsera (MTSR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Metsera Stock (NASDAQ:MTSR) Get Metsera alerts:Sign Up Key Stats Today's Range$70.13▼$70.7850-Day Range$52.15▼$83.1852-Week Range$12.30▼$83.86Volume27.90 million shsAverage Volume4.84 million shsMarket Capitalization$7.42 billionP/E RatioN/ADividend YieldN/APrice Target$55.50Consensus RatingReduce Company Overview Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York. Read More Receive MTSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metsera and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTSR Stock News HeadlinesPfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds ShiftApril 8, 2026 | finance.yahoo.comPfizer Releases Early Obesity Data Showing Up to 12.3% Weight LossFebruary 4, 2026 | finance.yahoo.comTrump and Bernie agree on thisDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.September 20 at 1:00 AM | Porter & Company (Ad)Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth StoryFebruary 4, 2026 | finance.yahoo.comWhy Pfizer's 2026 guidance miss is 'not a major surprise'December 16, 2025 | msn.comMetsera (MTSR): Evaluating Valuation After Sharp Share Price TurnaroundNovember 14, 2025 | finance.yahoo.comMetsera, Inc. Completes Merger and Restructures LeadershipNovember 14, 2025 | msn.comPfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: ReportNovember 13, 2025 | msn.comSee More Headlines MTSR Stock Analysis - Frequently Asked Questions How were Metsera's earnings last quarter? Metsera Inc. (NASDAQ:MTSR) issued its quarterly earnings results on Monday, July, 28th. The company reported ($0.66) earnings per share (EPS) for the quarter. When did Metsera IPO? Metsera (MTSR) raised $244 million in an initial public offering on Friday, January 31st 2025. The company issued 15,277,778 shares at $15.00-$17.00 per share. Company Calendar Last Earnings7/28/2025Today9/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MTSR Previous SymbolNASDAQ:MTSR CIK2040807 Webmetsera.com Phone(212) 784-6595FaxN/AEmployees81Year Founded2022Price Target and Rating Average Price Target for Metsera$55.50 High Price Target$57.00 Low Price Target$54.00 Potential Upside/Downside-21.3%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($6.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.13 million Net MarginsN/A Pretax MarginN/A Return on Equity-121.12% Return on Assets-53.54% Debt Debt-to-Equity RatioN/A Current Ratio4.25 Quick Ratio5.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book22.03Miscellaneous Outstanding Shares105,293,000Free FloatN/AMarket Cap$7.42 billion OptionableN/A BetaN/A Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:MTSR) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredNo Wallstreet. No Advisor. No Problem.Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...Awesomely | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredWhy This Small AI Company Holds 150 PatentsJeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
